Missed Opportunities

Missed Opportunities

As we approach the annual ADA money grab, this year in hot and humid Orlando attendees will see their fair share of way cool and whiz bang. (Something we talk about in our Special ADA Preview Report which is ready and available for purchase. To secure your copy contact me at dkliff@diabeticinvestor.com) What they likely won’t see is much in the most promising area of diabetes what we like to call Ozempic Cost Containment. (OCC)

The biggest issue with Ozempic, Wegovy, Mounjaro and Zepbound is cost. Each day more evidence mounts as to . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.